| Name | Sulindac |
| Description | Sulindac (Sulindac sulfoxide) is a sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. |
| In vitro | In intestinal tissues of Min/+ mice, Sulindac does not alter the levels of PGE2 and LTB4 but reduces the number of tumors. Within a mouse model of familial adenomatous polyposis, Sulindac decreases small intestine COX-2 and prostaglandin E (2), thereby inhibiting tumor formation. |
| In vivo | In colorectal cancer (CRC) cell lines, Sulindac and its metabolites sulindac sulfide and sulindac sulfone inhibit the NF-κB pathway, reducing IKKbeta kinase activity mediated by Sulindac. In HT-29 cells, Sulindac significantly reduces cell growth. Sulindac inhibits cell proliferation across various epithelial and fibroblast tumor cell lines. In CRC cell lines DLD1 and SW480, Sulindac suppresses beta-catenin/TCF-mediated gene transcription and decreases levels of non-phosphorylated beta-catenin. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.61 mM), Sonication is recommended.
Ethanol : 9 mg/mL (25.25 mM), Sonication is recommended.
DMSO : 250 mg/mL (701.44 mM), Sonication is recommended.
|
| Keywords | Sulindac | SIRT1 | pMMR | MK231 | MK 231 | migration | immunomodulatory agent | FDA | epithelial-mesenchymal transition (EMT) | COX | colorectal cancer (CRC) | Autophagy |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Guanidine hydrochloride | Hydroxychloroquine | Ethyl linoleate | Paeonol | Naringin | Trometamol | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Cosmetic Ingredient Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
United States
